REV7 counteracts DNA double-strand break resection and affects PARP inhibition

Nature

Volumn 521, Issue 7553, 2015, Pages 541-544

  Xu, Guotai ^a   Ross Chapman, J ^b   Brandsma, Inger ^c   Yuan, Jingsong ^d   Mistrik, Martin ^e   Bouwman, Peter ^a   Bartkova, Jirina ^f   Gogola, Ewa ^a   Warmerdam, Daniël ^a   Barazas, Marco ^a   Jaspers, Janneke E ^a   Watanabe, Kenji ^f   Pieterse, Mark ^a   Kersbergen, Ariena ^a   Sol, Wendy ^a   Celie, Patrick H N ^a   Schouten, Philip C ^a   Van Den Broek, Bram ^a   Salman, Ahmed ^b   Nieuwland, Marja ^a   De Rink, Iris ^a   De Ronde, Jorma ^a   Jalink, Kees ^a   Boulton, Simon J ^g   Chen, Junjie ^d   Van Gent, Dik C ^c   Bartek, Jiri ^e,f   Jonkers, Jos ^a   Borst, Piet ^a   Rottenberg, Sven ^a,h   more..

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e PALACKÝ UNIVERSITY   (Czech Republic)

^f DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^g IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^h UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; IMMUNOGLOBULIN CLASS; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; CHROMATIN; DNA BINDING PROTEIN; H2AFX PROTEIN, HUMAN; HISTONE; MAD2L2 PROTEIN, HUMAN; MAD2L2 PROTEIN, MOUSE; MDC1 PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NONHISTONE PROTEIN; NUCLEAR PROTEIN; PROTEIN MAD2; RNF168 PROTEIN, HUMAN; RNF8 PROTEIN, HUMAN; SIGNAL PEPTIDE; TP53BP1 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRP53BP1 PROTEIN, MOUSE; UBIQUITIN PROTEIN LIGASE;

ANTIBODY; CANCER; DNA; DRUG RESISTANCE; ENZYME ACTIVITY; INHIBITION; MUTATION; RECOMBINATION; RODENT; TUMOR;

ANIMAL CELL; ARTICLE; CELL LINE; CHROMATIN; DNA DAMAGE; DNA END JOINING REPAIR; DOUBLE STRANDED DNA BREAK; ENZYME INHIBITION; GENE; GENE FUNCTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REV7 GENE; REVERTANT; SURGERY; ANIMAL; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DRUG RESISTANCE; GENE REARRANGEMENT; GENETICS; METABOLISM; RECOMBINATION REPAIR;

ANIMALS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BRCA1 PROTEIN; CELL LINE; CHROMATIN; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA BREAKS, DOUBLE-STRANDED; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; HISTONES; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAD2 PROTEINS; MICE; NUCLEAR PROTEINS; POLY(ADP-RIBOSE) POLYMERASES; RECOMBINATIONAL DNA REPAIR; TRANS-ACTIVATORS; UBIQUITIN-PROTEIN LIGASES;

EID: 84930678981     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14328     Document Type: Article

References (31)

1. Roy, R., Chun, J. & Powell, S. N. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nature Rev. Cancer 12, 68-78 (2012).
2. Lee, J.-M., Ledermann, J. A. & Kohn, E. C. PARP Inhibitors for BRCA1/2 mutationassociated and BRCA-like malignancies. Ann. Oncol. 25, 32-40 (2013).
3. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
4. Lord, C. J. & Ashworth, A. Mechanisms of resistance to therapies targeting BRCAmutant cancers. Nature Med. 19, 1381-1388 (2013).
5. Ang, J. E. et al. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: amulti-institutional study. Clin. Cancer Res. 19, 5485-5493 (2013).
6. Chun, A. C.-S., Kok, K.-H. & Jin, D.-Y. REV7 is required for anaphase-promoting complex-dependent ubiquitination and degradation of translesion DNA polymerase REV1. Cell Cycle 12, 365-378 (2013).
7. Jaspers, J. E. et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 3, 68-81 (2013).
8. Listovsky, T. & Sale, J. E. Sequestration of CDH1 by MAD2L2 prevents premature APC/C activation prior to anaphase onset. J. Cell Biol. 203, 87-100 (2013).
9. Gan, G. N., Wittschieben, J. P., Wittschieben, B. Ø. & Wood, R. D. DNA polymerase zeta (pol zeta) in higher eukaryotes. Cell Res. 18, 174-183 (2008).
10. Hara, K. et al. Crystal structure of human REV7 in complex with a human REV3 fragment and structural implication of the interaction between DNA polymerase zeta and REV1. J. Biol. Chem. 285, 12299-12307 (2010).
11. Khalaj, M. et al. A missensemutation in Rev7 disrupts formation of Polf, impairing mouse development and repair of genotoxic agent-induced DNA lesions. J. Biol. Chem. 289, 3811-3824 (2014).
12. Stap, J. et al. Induction of linear tracks of DNA double-strand breaks by alphaparticle irradiation of cells. Nature Methods 5, 261-266 (2008).
13. Fanning, E., Klimovich, V. & Nager, A. R. A dynamic model for replication protein A (RPA) function in DNA processing pathways. Nucleic Acids Res. 34, 4126-4137 (2006).
14. Sartori, A. A. et al. HumanCtIP promotes DNA end resection. Nature 450, 509-514 (2007).
15. Bouwman, P. et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nature Struct. Mol. Biol. 17, 688-695 (2010).
16. Pierce, A. J., Johnson, R. D., Thompson, L. H. & Jasin, M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 13, 2633-2638 (1999).
17. Bunting, S. F. et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141, 243-254 (2010).
18. Zimmermann, M. & de Lange, T. 53BP1: pro choice inDNA repair. Trends Cell Biol. 24, 108-117 (2014).
19. Chapman, J. R. et al. RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection. Mol. Cell 49, 858-871 (2013).
20. Muramatsu, M. et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102, 553-563 (2000).
21. Schenten, D. et al. Pol f ablation in B cells impairs the germinal center reaction, class switch recombination, DNA break repair, and genome stability. J. Exp. Med. 206, 477-490 (2009).
22. Kikuchi, S., Hara, K., Shimizu, T., Sato, M. & Hashimoto, H. Structural basis of recruitment ofDNApolymerase f by interaction betweenREV1andREV7proteins. J. Biol. Chem. 287, 33847-33852 (2012).
23. Evers, B. et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin. Cancer Res. 14, 3916-3925 (2008).
24. Fradet-Turcotte, A. et al. 53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark. Nature 499, 50-54 (2013).
25. Watanabe, S. et al. JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1-mediated chromatin response toDNA breaks.Nature Struct.Mol. Biol.20, 1425-1433 (2013).
26. Doil, C. et al. RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell 136, 435-446 (2009).
27. Stewart, G. S. et al. The RIDDLE syndrome protein mediates a ubiquitindependent signaling cascade at sites of DNA damage. Cell 136, 420-434 (2009).
28. Stap, J. et al. Induction of linear tracks of DNAdouble-strand breaks by a-particle irradiation of cells. Nature Methods 5, 261-266 (2008).
29. de Jager,M. et al. DNA-binding and strand-annealing activities of humanMre11: implications for its roles in DNA double-strand break repair pathways. Nucleic Acids Res. 29, 1317-1325 (2001).
30. Bouwman, P. et al. A high-throughput functional complementation assay for classification of BRCA1 missense variants. Cancer Discov. 3, 1142-1155 (2013).
31. Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870 (2005).